Advanced Cervical Cancer Treatment Advances: Alphamab Oncology's Dual-Action Therapy Enters Phase 2 Clinical Development in China

Alphamab Oncology (9966.HK) has achieved a significant regulatory milestone as China’s National Medical Products Administration approved the Investigational New Drug (IND) application for JSKN033, moving the compound into Phase 2 clinical evaluation for treating advanced cervical cancer patients who have not received prior systemic therapy.

The therapeutic approach represents an innovative combination strategy, utilizing JSKN033—a high-concentration subcutaneous formulation that merges two distinct mechanisms: a HER2-targeting bispecific antibody-drug conjugate (ADC) and a PD-L1 immune checkpoint inhibitor. This dual-mechanism design aims to simultaneously attack cancer cells through targeted delivery and immune system activation.

The forthcoming JSKN033-202 trial will assess the safety profile, clinical efficacy, and detailed pharmacokinetic and pharmacodynamic characteristics of JSKN033 when administered alongside platinum-based chemotherapy regimens. Participating patients will receive either chemotherapy combined with the investigational agent alone, or in conjunction with bevacizumab, an anti-angiogenic monoclonal antibody that restricts tumor blood supply.

Alphamab’s development pipeline is expanding globally, with concurrent Phase I/II trials underway across China and Australia, evaluating JSKN033’s potential across broader solid tumor indications. This regulatory acceptance reflects growing recognition of combination immunotherapy and targeted drug delivery as promising approaches in oncology, particularly for malignancies affecting vulnerable patient populations seeking improved treatment alternatives.